Search

Gossamer Bio Inc

Lezárt

SzektorEgészségügy

0.17 13.33

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

0.15

Maximum

0.16

Fő mutatók

By Trading Economics

Bevétel

64M

17M

Értékesítés

-7.7M

9.2M

Egy részvényre jutó nyereség

-0.2

Profit margin

182.94

Munkavállalók

161

EBITDA

-28M

-71M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+613.33% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-18M

68M

Előző nyitás

-13.16

Előző zárás

0.17

Hangulat hírek alapján

By Acuity

76%

24%

318 / 340 Rangsor szerint Healthcare

Gossamer Bio Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 22. 00:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market gains despite no specific company news identified.

2026. aug. 21. 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following broader market gains despite earlier lower trading. No specific news was identified for the move.

2026. aug. 20. 23:01 UTC

Gossamer Bio shares are lower in after-market trading, reflecting broader market pressures following Walmart's disappointing sales growth and guidance.

2026. aug. 19. 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following a notable peak earlier in the session. The stock remains below its 20-day moving average.

2026. aug. 18. 23:01 UTC

Gossamer Bio Inc shares rose in after-market trading following Tuesday's close, though no specific news was identified to explain the movement.

2026. aug. 17. 23:31 UTC

Gossamer Bio Inc shares are sharply higher in after-market trading, rising significantly despite being below its 20-day moving average and recent declines.

2026. aug. 15. 00:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, though no specific news explains the movement. The price remains below its 20-day moving average.

2026. aug. 14. 22:51 UTC

Gossamer Bio Inc. shares are higher in after-market hours, despite disappointing U.S. retail sales data influencing broader market sentiment.

2026. aug. 13. 23:01 UTC

News

Gossamer Bio reported second-quarter net income of $16.9 million and plans to submit a New Drug Application for seralutinib in September 2026. Shares are higher in after-market trading.

2026. aug. 12. 23:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, continuing a strong performance since July 13, despite earlier fluctuations during the session.

2026. aug. 11. 23:11 UTC

No specific news was identified for Gossamer Bio Inc. in after-market trading, with shares effectively unchanged since Tuesday's close.

2026. aug. 10. 23:01 UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting strong performance and positioning above the 20-day moving average. No specific news was identified.

2026. aug. 7. 19:56 UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

2026. aug. 6. 23:12 UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

2026. aug. 5. 23:36 UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

2026. aug. 4. 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

2026. aug. 3. 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

2026. aug. 1. 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

2026. júl. 31. 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

2026. júl. 30. 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

2026. júl. 29. 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

2026. júl. 28. 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

2026. júl. 27. 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

2026. júl. 24. 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

2026. júl. 23. 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

2026. júl. 22. 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

2026. júl. 21. 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

2026. júl. 20. 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Társak összehasonlítása

Árváltozás

Gossamer Bio Inc Előrejelzés

Célár

By TipRanks

613.33% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 1.07 USD  613.33%

Magas 2 USD

Alacsony 0.28 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Gossamer Bio Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

2

Vétel

2

Tartás

1

Eladás

Hangulat

By Acuity

318 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Nagyon erős bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
help-icon Live chat